DS-6000a
Daiichi Sankyo
['rcc,(-irccs),(-srcc),(-urcc)', 'ovarian']
 presenting ds-6000a - cdh6 adc in #asco22 dev ther orals: ph 1 - early efficacy in refractory ovarian ca (5/20 prs - and drops in ca125 in 8/17) and rcc (1/10 pr). aes: low-grade n/v, fatigue. encouraging signals for this adc - expansions ongoing - fantastic talk! 
Chief Scientific Officer, Sarah Cannon Research Institute; Thoracic Medical Oncology, Tennessee Oncology